Vivos TherapeuticsVVOS -9.05%41 Net Debt Paydown Yield % is -172.83% as of Jul. 03, 2026. GuruFocus rates VVOS with a GF Score™ of 41/100 and a GF Value™ of $1.15 (Possible Value Trap). The stock has 6 warning signs investors should review. Among 771 Medical Devices & Instruments companies, Vivos Therapeutics ranks worse than 99.48% on this metric.
Net Debt Paydown Yield % is a metric that evaluates the total amount of debt a company has paid in relation to its market capitalization. It is a measure of a company's willingness and ability to reduce its debt.
As of today, Vivos Therapeutics's Net Debt Paydown Yield % was -172.83%.
Vivos Therapeutics (NAS:VVOS) Net Debt Paydown Yield % Explanation
Net Debt Paydown Yield % is the change in average of four quarters of company's total debt over a company's market cap. Assuming the total value of a company remains that same, shareholder value is increased as debt is reduced. In other words, it is a measure of the willingness and ability of a firm's management to pay down debt. Companies that have high debt paydown yields indicate that they are more aggressive with paying down debt.
In the calculation of Net Debt Paydown Yield %, we use the reductions of TTM average total debt one-year-ago and TTM average total debt at present, divided by its Market Cap.
Vivos Therapeutics Net Debt Paydown Yield % Related Terms
Vivos Therapeutics Net Debt Paydown Yield % Historical Data
* Premium members only.
The historical data trend for Vivos Therapeutics's Net Debt Paydown Yield % can be seen below:
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
VVOS vs XAIR, TNON, BMRA: Net Debt Paydown Yield % Comparison
For the Medical Devices subindustry, Vivos Therapeutics's Net Debt Paydown Yield %, along with its competitors' market caps and Net Debt Paydown Yield % data, can be viewed below:
* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.
Vivos Therapeutics Net Debt Paydown Yield % vs Medical Devices & Instruments Industry
For the Medical Devices & Instruments industry and Healthcare sector, Vivos Therapeutics's Net Debt Paydown Yield % distribution charts can be found below:
* The bar in red indicates where Vivos Therapeutics's Net Debt Paydown Yield % falls into.
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
* All the data are calculated by TTM values. Note that if a companies is traded in several exchanges, then we calculate the company level data for Net Debt Paydown Yield % using the primary share class stock data. The calculation result in definition page is for demonstration purpose only, and it's showing the share class level data. Therefore, the numbers in the calculation may differ from elsewhere if the stock is not a primary share.
What does a Net Debt Paydown Yield % of -172.83% mean?
Vivos Therapeutics (VVOS) has a Net Debt Paydown Yield % of -172.83% as of Jul. 03, 2026. Net Debt Paydown Yield is a metric that evaluates the total amount of debt a company has paid in relation to its market capitalization. This metric provides insight into a company's willingness and ability to reduce its debt using free cash flow. View historical data on Vivos Therapeutics and its competitors. According to the industry distribution chart, Vivos Therapeutics ranks #767 out of 771 companies in the Medical Devices & Instruments industry, placing it in the top 99.5%.
Is Vivos Therapeutics' Net Debt Paydown Yield % too high?
Vivos Therapeutics' current Net Debt Paydown Yield % is -172.83%. Based on the distribution chart, Vivos Therapeutics ranks #767 out of 771 companies in the Medical Devices & Instruments industry, which is in the bottom quartile relative to peers. Overall, Vivos Therapeutics has a GF Score™ of 41/100 and is considered Possible Value Trap, reflecting its overall financial health beyond just this single metric.
How does Vivos Therapeutics' Net Debt Paydown Yield % compare to XAIR and TNON?
According to the Medical Devices & Instruments industry distribution chart, Vivos Therapeutics ranks #767 out of 771 companies for Net Debt Paydown Yield %. This places Vivos Therapeutics in the lower half of its industry. The industry median Net Debt Paydown Yield % is 0.01. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good Net Debt Paydown Yield % for a Medical Devices & Instruments company?
The median Net Debt Paydown Yield % among Medical Devices & Instruments companies is 0.01, based on 771 companies in the industry. Companies in the top quartile (top 25%) have a Net Debt Paydown Yield % significantly above this median, while those in the bottom quartile fall well below. However, Net Debt Paydown Yield % should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high Net Debt Paydown Yield % mean?
A high Net Debt Paydown Yield % can signal that a stock is expensive relative to its fundamentals. Net Debt Paydown Yield is a metric that evaluates the total amount of debt a company has paid in relation to its market capitalization. This metric provides insight into a company's willingness and ability to reduce its debt using free cash flow. View historical data on Vivos Therapeutics and its competitors. For the Medical Devices & Instruments industry, the median Net Debt Paydown Yield % is 0.01 — values significantly above this may indicate overvaluation, while values below may suggest a bargain or underlying issues. Vivos Therapeutics's current Net Debt Paydown Yield % is -172.83%. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is Vivos Therapeutics stock overvalued right now?
Based on GuruFocus' analysis, Vivos Therapeutics (VVOS) is currently considered Possible Value Trap. The stock's GF Value™ is $1.15, compared to a current price of $0.45 — trading 60.6% below its estimated fair value. The current Net Debt Paydown Yield % is -172.83%. Vivos Therapeutics' overall GF Score™ is 41/100 with 6 warning signs to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is Net Debt Paydown Yield % calculated?
Net Debt Paydown Yield % is calculated from a company's financial statements. For Vivos Therapeutics (VVOS), the current Net Debt Paydown Yield % is -172.83% as of Jul. 03, 2026. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.
Is Vivos Therapeutics (VVOS) Overvalued in 2026?
Based on GuruFocus' analysis, Vivos Therapeutics stock appears to be undervalued.
The current stock price of $0.45 is trading 60.6% below its estimated GF Value™ of $1.15.
GuruFocus considers Vivos Therapeutics to be Possible Value Trap.
Key valuation signals for VVOS:
Net Debt Paydown Yield %: -172.83%
GF Value™: $1.15 vs. price of $0.45 (60.6% below fair value)
No single metric tells the full story. See the VVOS stock analysis page for a complete view including 30-year financials, guru trades, and insider activity.
Vivos Therapeutics Inc is a medical technology company. It is focused on the development and commercialization of a technology offering non-surgical, non-invasive, non-pharmaceutical, and low-cost solution for patients with sleep-disordered breathing (SDB), including mild-to-moderate obstructive sleep apnea (OSA). The company provides treatment for mild-to-moderate OSA involves customized oral appliances and protocols called the Vivos System. The Vivos systme is an therapeutic protocol, which often combines the use of customized oral appliance specifications and proprietary clinical treatments developed by company and prescribed by specially trained dentists in cooperation with their medical colleagues.
41GF Score
Get the complete analysis for VVOS
Net Debt Paydown Yield % is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.
Quick Browse
Personalize
Premium Gurus 
Create New Portfolio
VVOS has been successfully added to your 
